

Josep Lupon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4301890/publications.pdf>

Version: 2024-02-01

212
papers

6,145
citations

66343

42
h-index

102487

66
g-index

233
all docs

233
docs citations

233
times ranked

7211
citing authors

#	ARTICLE	IF	CITATIONS
1	Head-to-Head Comparison of 2 Myocardial Fibrosis Biomarkers for Long-Term Heart Failure Risk Stratification. <i>Journal of the American College of Cardiology</i> , 2014, 63, 158-166.	2.8	222
2	Comparison of self-care behaviors of heart failure patients in 15 countries worldwide. <i>Patient Education and Counseling</i> , 2013, 92, 114-120.	2.2	211
3	Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. <i>Circulation</i> , 2019, 140, 31-41.	1.6	195
4	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure. <i>Circulation</i> , 2018, 137, 286-297.	1.6	157
5	Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. <i>European Journal of Heart Failure</i> , 2017, 19, 1615-1623.	7.1	149
6	Impact of Frailty on Mortality and Hospitalization in Chronic Heart Failure: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2018, 7, e008251.	3.7	140
7	Soluble Nephilysin Is Predictive of Cardiovascular Death and Heart Failure Hospitalization in Heart Failure Patients. <i>Journal of the American College of Cardiology</i> , 2015, 65, 657-665.	2.8	137
8	Dynamic Trajectories of Left Ventricular Ejection Fraction in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 72, 591-601.	2.8	132
9	Combined use of high-sensitivity ST2 and NT-proBNP to improve the prediction of death in heart failure. <i>European Journal of Heart Failure</i> , 2012, 14, 32-38.	7.1	130
10	sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2309-2320.	2.8	126
11	Estimated Glomerular Filtration Rate and Prognosis in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1709-1715.	2.8	121
12	Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality. <i>Circulation</i> , 2018, 137, 1320-1330.	1.6	121
13	Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN) Tj ETQq1 1 0,784314 rgBT /Ove	2.5	97
14	Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score. <i>International Journal of Cardiology</i> , 2015, 184, 337-343.	1.7	92
15	Soluble ST2 Serum Concentration and Renal Function in Heart Failure. <i>Journal of Cardiac Failure</i> , 2013, 19, 768-775.	1.7	87
16	Advanced interatrial block predicts new-onset atrial fibrillation and ischemic stroke in patients with heart failure: The "Bayes' Syndrome-HF" study. <i>International Journal of Cardiology</i> , 2018, 271, 174-180.	1.7	71
17	Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes. <i>JACC Basic To Translational Science</i> , 2019, 4, 831-840.	4.1	65
18	Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patients. <i>European Journal of Heart Failure</i> , 2018, 20, 67-75.	7.1	63

#	ARTICLE	IF	CITATIONS
19	Depression, antidepressants, and long-term mortality in heart failure. <i>International Journal of Cardiology</i> , 2013, 167, 1217-1225.	1.7	62
20	Mortalidad y causas de muerte en pacientes con insuficiencia cardiaca: experiencia de una unidad especializada multidisciplinaria. <i>Revista Espanola De Cardiologia</i> , 2010, 63, 303-314.	1.2	60
21	Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review. <i>European Journal of Heart Failure</i> , 2021, 23, 1445-1457.	7.1	60
22	Weight Loss in Obese Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2016, 5, e002468.	3.7	59
23	CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction. <i>American Journal of Medicine</i> , 2020, 133, 370-380.e4.	1.5	58
24	Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial IRON Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e014254.	3.7	58
25	Sex and age differences in fragility in a heart failure population. <i>European Journal of Heart Failure</i> , 2005, 7, 798-802.	7.1	57
26	Combined Use of the Novel Biomarkers High-Sensitivity Troponin T and ST2 for Heart Failure Risk Stratification vs Conventional Assessment. <i>Mayo Clinic Proceedings</i> , 2013, 88, 234-243.	3.0	57
27	Usefulness of Body Mass Index to Characterize Nutritional Status in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2011, 108, 1166-1170.	1.6	56
28	Six-Month Outcome in Patients With Myocardial Infarction Initially Admitted to Tertiary and Nontertiary Hospitals <small>fn1fn1This project was funded by Grant 92/0009 from the Fondo de Investigaci3n Sanitaria, Madrid and by Grant CIRIT/SGR 9500167 from the Generalitat de Catalunya, Barcelona, Spain.fn2fn2To discuss this article on-line, visit the ACC Home Page at www.acc.org/members and click on the JACC Forum.</small> <i>Journal of the American College of Cardiology</i> , 1997, 30, 1187-1192.	2.8	55
29	Statins in Heart Failure: The Paradox Between Large Randomized Clinical Trials and Real Life. <i>Mayo Clinic Proceedings</i> , 2012, 87, 555-560.	3.0	55
30	Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. <i>American Heart Journal</i> , 2012, 163, 821-828.	2.7	54
31	Heart Failure With Preserved Ejection Fraction Infrequently Evolves Toward a Reduced Phenotype in Long-Term Survivors. <i>Circulation: Heart Failure</i> , 2019, 12, e005652.	3.9	53
32	The obesity paradox in heart failure: Is etiology a key factor?. <i>International Journal of Cardiology</i> , 2013, 166, 601-605.	1.7	52
33	Renal function largely influences Galectin-3 prognostic value in heart failure. <i>International Journal of Cardiology</i> , 2014, 177, 171-177.	1.7	52
34	Impact of diabetes on the predictive value of heart failure biomarkers. <i>Cardiovascular Diabetology</i> , 2016, 15, 151.	6.8	51
35	No benefit from the obesity paradox for diabetic patients with heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 851-858.	7.1	49
36	The Dynamics of Cardiovascular Biomarkers in non-Elite Marathon Runners. <i>Journal of Cardiovascular Translational Research</i> , 2017, 10, 206-208.	2.4	47

#	ARTICLE	IF	CITATIONS
37	Trends in modes of death in heart failure over the last two decades: less sudden death but cancer deaths on the rise. <i>European Journal of Heart Failure</i> , 2019, 21, 1259-1266.	7.1	46
38	Fragility is a key determinant of survival in heart failure patients. <i>International Journal of Cardiology</i> , 2014, 175, 62-66.	1.7	45
39	Prognostic Value and Kinetics of Soluble Natriuretic Peptide in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 641-644.	4.1	44
40	Soluble ST2 for Prognosis and Monitoring in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2389-2392.	2.8	43
41	The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2128-2136.	2.8	43
42	Patient's Education by Nurse: What We Really do Achieve?. <i>European Journal of Cardiovascular Nursing</i> , 2005, 4, 107-111.	0.9	42
43	Quality of life monitoring in ambulatory heart failure patients: temporal changes and prognostic value. <i>European Journal of Heart Failure</i> , 2013, 15, 103-109.	7.1	42
44	Body mass index, body fat, and nutritional status of patients with heart failure: The PLICA study. <i>Clinical Nutrition</i> , 2015, 34, 1233-1238.	5.0	42
45	Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain). <i>BMJ Open</i> , 2017, 7, e018719.	1.9	40
46	Usefulness of Right Ventricular to Pulmonary Circulation Coupling as an Indicator of Risk for Recurrent Admissions in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2019, 124, 567-572.	1.6	38
47	Patients' Self-Care Improvement with Nurse Education Intervention in Spain Assessed by the European Heart Failure Self-Care Behaviour Scale. <i>European Journal of Cardiovascular Nursing</i> , 2008, 7, 16-20.	0.9	37
48	Validación de la versión española del Kansas City Cardiomyopathy Questionnaire. <i>Revista Española De Cardiología</i> , 2011, 64, 51-58.	1.2	34
49	Head-to-head comparison of high-sensitivity troponin T and sensitive-contemporary troponin I regarding heart failure risk stratification. <i>Clinica Chimica Acta</i> , 2013, 426, 18-24.	1.1	34
50	Nurse Evaluation of Patients in a New Multidisciplinary Heart Failure Unit in Spain. <i>European Journal of Cardiovascular Nursing</i> , 2004, 3, 61-69.	0.9	33
51	Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients. <i>BMC Geriatrics</i> , 2018, 18, 109.	2.7	33
52	Meteorin-like/Meteorin- β protects heart against cardiac dysfunction. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	33
53	Comentarios a la guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardíaca aguda y crónica 2012. Un informe del Grupo de Trabajo del Comité de Guías de Práctica Clínica de la Sociedad Española de Cardiología. <i>Revista Española De Cardiología</i> , 2012, 65, 874-878.	1.2	32
54	Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction. <i>International Journal of Cardiology</i> , 2018, 257, 188-192.	1.7	32

#	ARTICLE	IF	CITATIONS
55	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. <i>International Journal of Cardiology</i> , 2019, 277, 166-172.	1.7	32
56	Punto de corte Å³ptimo de NT-proBNP para el diagnÅ³stico de insuficiencia cardiaca mediante un test de determinaciÅ³n rÅ³pida en atenciÅ³n primaria. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 613-619.	1.2	31
57	ST2 Pathogenetic Profile in Ambulatory Heart Failure Patients. <i>Journal of Cardiac Failure</i> , 2015, 21, 355-361.	1.7	31
58	Neprilysin and Natriuretic Peptide Regulation in Heart Failure. <i>Current Heart Failure Reports</i> , 2016, 13, 151-157.	3.3	31
59	Transitions of Care Between Acute and Chronic Heart Failure: Critical Steps in the Design of a Multidisciplinary Care Model for the Prevention of Rehospitalization. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 951-961.	0.6	30
60	Depression as Measured by PHQ-9 Versus Clinical Diagnosis as an Independent Predictor of Long-Term Mortality in a Prospective Cohort of Medical Inpatients. <i>Psychosomatic Medicine</i> , 2017, 79, 273-282.	2.0	30
61	ST2 in Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e005582.	3.9	30
62	Mini nutritional assessment is a better predictor of mortality than subjective global assessment in heart failure out-patients. <i>Clinical Nutrition</i> , 2019, 38, 2740-2746.	5.0	30
63	Evaluation of a telemedicine system for heart failure patients: feasibility, acceptance rate, satisfaction and changes in patient behavior: results from the CARME (Catalan Remote Management Evaluation) study. <i>European Journal of Cardiovascular Nursing</i> , 2012, 11, 410-418.	0.9	28
64	Long-term Prognostic Value for Patients with Chronic Heart Failure of Estimated Glomerular Filtration Rate Calculated with the New CKD-EPI Equations Containing Cystatin C. <i>Clinical Chemistry</i> , 2014, 60, 481-489.	3.2	28
65	Educational level and self-care behaviour in patients with heart failure before and after nurse educational intervention. <i>European Journal of Cardiovascular Nursing</i> , 2014, 13, 459-465.	0.9	28
66	A novel wearable vest for tracking pulmonary congestion in acutely decompensated heart failure. <i>International Journal of Cardiology</i> , 2014, 177, 199-201.	1.7	28
67	Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1751-1759.	1.8	28
68	Association Between Norepinephrine Levels and Abnormal Iron Status in Patients With Chronic Heart Failure: Is Iron Deficiency More Than a Comorbidity?. <i>Journal of the American Heart Association</i> , 2019, 8, e010887.	3.7	27
69	Cardiovascular disease and COVID-19: les liaisons dangereuses. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1017-1025.	1.8	27
70	Prediction of survival and magnitude of reverse remodeling using the ST2-R2 score in heart failure: A multicenter study. <i>International Journal of Cardiology</i> , 2016, 204, 242-247.	1.7	26
71	Proteomic signature of circulating extracellular vesicles in dilated cardiomyopathy. <i>Laboratory Investigation</i> , 2018, 98, 1291-1299.	3.7	26
72	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T. <i>European Journal of Heart Failure</i> , 2020, 22, 2078-2088.	7.1	26

#	ARTICLE	IF	CITATIONS
73	Association between right-sided cardiac function and ultrasound-based pulmonary congestion on acutely decompensated heart failure: findings from a pooled analysis of four cohort studies. <i>Clinical Research in Cardiology</i> , 2021, 110, 1181-1192.	3.3	26
74	Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Nephilysin vs NT-proBNP. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 1075-1084.	0.6	23
75	Soluble neprilysin retains catalytic activity in heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 684-685.	0.6	23
76	Entrenamiento de la musculatura inspiratoria y la electroestimulaci3n muscular funcional en el tratamiento de la insuficiencia cardiaca con funci3n sist3lica conservada: estudio TRAINING-HF. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 288-297.	1.2	23
77	Decoding empagliflozin4s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence. <i>Scientific Reports</i> , 2021, 11, 12025.	3.3	23
78	Effect of Fragility on Quality of Life in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2013, 112, 1785-1789.	1.6	22
79	Usefulness of hospital admission risk stratification for predicting nonfatal acute myocardial infarction or death six months later in unstable angina pectoris. <i>American Journal of Cardiology</i> , 1999, 84, 963-969.	1.6	21
80	Early Postdischarge STOP-HF-Clinic Reduces 30-day Readmissions in Old and Frail Patients With Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 631-638.	0.6	21
81	ST2 and left ventricular remodeling after ST-segment elevation myocardial infarction: A cardiac magnetic resonance study. <i>International Journal of Cardiology</i> , 2018, 270, 336-342.	1.7	21
82	Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction. <i>European Journal of Preventive Cardiology</i> , 2020, , 204748732092761.	1.8	21
83	Mini Nutritional Assessment Short Form is a morbi-mortality predictor in outpatients with heart failure and mid-range left ventricular ejection fraction. <i>Clinical Nutrition</i> , 2020, 39, 3395-3401.	5.0	21
84	Serum Nephilysin and Recurrent Admissions in Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	20
85	Barcelona Bio4HF Calculator Version 2.0: incorporation of angiotensin II receptor blocker nephilysin inhibitor (ARNI) and risk for heart failure hospitalization. <i>European Journal of Heart Failure</i> , 2018, 20, 938-940.	7.1	20
86	Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data. <i>Clinical Research in Cardiology</i> , 2021, 110, 1280-1291.	3.3	20
87	NT-proBNP for Risk Prediction in Heart4Failure. <i>JACC: Heart Failure</i> , 2021, 9, 653-663.	4.1	20
88	Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach. <i>Journal of Clinical Medicine</i> , 2020, 9, 1110.	2.4	19
89	Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond. <i>Cardiac Failure Review</i> , 2022, 8, e12.	3.0	19
90	Importance of iron deficiency in patients with chronic heart failure as a predictor of mortality and hospitalizations: insights from an observational cohort study. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 206.	1.7	18

#	ARTICLE	IF	CITATIONS
91	Niveles sÃ©ricos de miostatina en insuficiencia cardiaca crÃ³nica. Revista Espanola De Cardiologia, 2010, 63, 992-996.	1.2	17
92	Pulmonary hypertension and right ventricular dysfunction in heart failure: prognosis and 15-year prospective longitudinal trajectories in survivors. European Journal of Heart Failure, 2020, 22, 1214-1225.	7.1	17
93	Heart failure with mid-range ejection fraction: a transition phenotype?. European Journal of Heart Failure, 2017, 19, 1635-1637.	7.1	16
94	Prognostic Value of New-Generation Troponins in ST-Segment-Elevation Myocardial Infarction in the Modern Era: The RUTI-STEMI Study. Journal of the American Heart Association, 2017, 6, .	3.7	16
95	Left ventricular ejection fraction in heart failure: a clinician's perspective about a dynamic and imperfect parameter, though still convenient and a cornerstone for patient classification and management. European Journal of Heart Failure, 2018, 20, 433-435.	7.1	16
96	A bio-clinical approach for prediction of sudden cardiac death in outpatients with heart failure: The ST2-SCD score. International Journal of Cardiology, 2019, 293, 148-152.	1.7	16
97	Functional tricuspid regurgitation and recurrent admissions in patients with acute heart failure. International Journal of Cardiology, 2019, 291, 83-88.	1.7	16
98	Trends in Short- and Long-Term ST-Segment-Elevation Myocardial Infarction Prognosis Over 3 Decades: A Mediterranean Population-Based ST-Segment-Elevation Myocardial Infarction Registry. Journal of the American Heart Association, 2020, 9, e017159.	3.7	16
99	Biomarkers in Heart Failure with Preserved Ejection Fraction. Cardiac Failure Review, 0, 8, .	3.0	16
100	Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction. Journal of Clinical Medicine, 2020, 9, 831.	2.4	15
101	Nepilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study. ESC Heart Failure, 2020, 7, 559-566.	3.1	15
102	Circulating levels and prognostic cutoffs of sST2, hs-TnT, and NT-proBNP in women vs. men with chronic heart failure. ESC Heart Failure, 2022, 9, 2084-2095.	3.1	15
103	Limited Value of Cystatin-C over Estimated Glomerular Filtration Rate for Heart Failure Risk Stratification. PLoS ONE, 2012, 7, e51234.	2.5	14
104	Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction: a pilot study. ESC Heart Failure, 2020, 7, 118-123.	3.1	14
105	Short- and Long-Term Mortality Trends in STEMI-Cardiogenic Shock over Three Decades (1989-2018): The Ruti-STEMI-Shock Registry. Journal of Clinical Medicine, 2020, 9, 2398.	2.4	14
106	Rehospitalization burden and morbidity risk in patients with heart failure with mid-range ejection fraction. ESC Heart Failure, 2020, 7, 1007-1014.	3.1	14
107	Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018. Scientific Reports, 2021, 11, 732.	3.3	14
108	CinÃ©tica de la hemoglobina y pronÃ³stico a largo plazo en insuficiencia cardiaca. Revista Espanola De Cardiologia, 2016, 69, 820-826.	1.2	13

#	ARTICLE	IF	CITATIONS
109	Primary Ventricular Fibrillation in the Primary Percutaneous Coronary Intervention ST-Segment Elevation Myocardial Infarction Era (from the "Codi IAM" Multicenter Registry). <i>American Journal of Cardiology</i> , 2018, 122, 529-536.	1.6	13
110	Lung Ultrasound for Heart Failure Diagnosis in Primary Care. <i>Journal of Cardiac Failure</i> , 2020, 26, 824-831.	1.7	13
111	Six-month outcome in unstable angina patients without previous myocardial infarction according to the use of tertiary cardiologic resources. <i>Journal of the American College of Cardiology</i> , 1999, 34, 1947-1953.	2.8	12
112	Ageing and Heart Rate in Heart Failure: Clinical Implications for Long-term Mortality. <i>Mayo Clinic Proceedings</i> , 2015, 90, 765-772.	3.0	12
113	Serum neprilysin and recurrent hospitalizations after acute heart failure. <i>International Journal of Cardiology</i> , 2016, 220, 742-744.	1.7	12
114	Wearable vest for pulmonary congestion tracking and prognosis in heart failure: A pilot study. <i>International Journal of Cardiology</i> , 2016, 215, 77-79.	1.7	12
115	First-in-man Safety and Efficacy of the Adipose Graft Transposition Procedure (AGTP) in Patients With a Myocardial Scar. <i>EBioMedicine</i> , 2016, 7, 248-254.	6.1	12
116	Bloodstream Amyloid-beta (1-40) Peptide, Cognition, and Outcomes in Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 924-932.	0.6	12
117	Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of Heart Failure With Preserved Ejection Fraction: The TRAINING-HF Trial. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 288-297.	0.6	12
118	Soluble Neprilysin and Corin Concentrations in Relation to Clinical Outcome in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 85-95.	4.1	12
119	Circulating Endothelial Progenitor Cells: Potential Biomarkers for Idiopathic Dilated Cardiomyopathy. <i>Journal of Cardiovascular Translational Research</i> , 2016, 9, 80-84.	2.4	11
120	Acute-phase dynamics and prognostic value of growth differentiation factor-15 in ST-elevation myocardial infarction. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1093-1101.	2.3	11
121	Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 3014-3025.	3.1	11
122	Estimated creatinine clearance: a determinant prognostic factor in heart failure. <i>Medicina Clínica</i> , 2008, 131, 47-51.	0.6	10
123	Obesidad y pronóstico a largo plazo en la insuficiencia cardiaca: la paradoja continúa. <i>Revista Espanola De Cardiologia</i> , 2010, 63, 1210-1212.	1.2	10
124	High-sensitivity troponin T in asymptomatic severe aortic stenosis. <i>Biomarkers</i> , 2019, 24, 334-340.	1.9	10
125	Use of intravenous iron in patients with iron deficiency and chronic heart failure: Real-world evidence. <i>European Journal of Internal Medicine</i> , 2020, 80, 91-98.	2.2	10
126	Advanced remote care for heart failure in times of COVID-19 using an implantable pulmonary artery pressure sensor: the new normal. <i>European Heart Journal Supplements</i> , 2020, 22, P29-P32.	0.1	10

#	ARTICLE	IF	CITATIONS
127	The real-life value of ST2 monitoring during heart failure decompensation: impact on long-term readmission and mortality. <i>Biomarkers</i> , 2016, 21, 225-232.	1.9	9
128	Extracellular vesicles do not contribute to higher circulating levels of soluble <sc>LRP</sc>1 in idiopathic dilated cardiomyopathy. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 3000-3009.	3.6	9
129	Rationale and design of a multicentre, prospective, randomised, controlled clinical trial to evaluate the efficacy of the adipose graft transposition procedure in patients with a myocardial scar: the AGTP II trial. <i>BMJ Open</i> , 2017, 7, e017187.	1.9	9
130	Determination of HLA*EA, *EB, *EC, *EDRB1 and *EDQB1 allele and haplotype frequencies in heart failure patients. <i>ESC Heart Failure</i> , 2019, 6, 388-395.	3.1	9
131	Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline. <i>Cardiovascular Diabetology</i> , 2020, 19, 38.	6.8	9
132	Thirst and factors associated with frequent thirst in patients with heart failure in Spain. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2021, 50, 86-91.	1.6	9
133	Destination Therapy with Left Ventricular Assist Devices in Non-transplant Centres: The Time is Right. <i>European Cardiology Review</i> , 2020, 15, e19.	2.2	9
134	Can Natriuretic Peptides be Used to Guide Therapy?. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2016, 27, 208-16.	0.7	9
135	Risk Prediction Tools in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 267.	4.1	8
136	Neprilisina: indicaciones, expectativas y retos. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 647-649.	1.2	8
137	Circulating monocyte subsets and heart failure prognosis. <i>PLoS ONE</i> , 2018, 13, e0204074.	2.5	8
138	La fibrosis intersticial miocárdica en la era de la medicina de precisión. El fenotipado basado en biomarcadores para un tratamiento personalizado. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 248-254.	1.2	8
139	Análisis de la demanda telefónica en una unidad de insuficiencia cardiaca: motivos de consulta y utilización de recursos. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 914-915.	1.2	7
140	Neprilysin: Indications, Expectations, and Challenges. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 647-649.	0.6	7
141	Hemoglobin Kinetics and Long-term Prognosis in Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 820-826.	0.6	7
142	Benzodiazepine Use and Long-Term Mortality in Real-Life Chronic Heart Failure Outpatients: A Cohort Analysis. <i>Psychotherapy and Psychosomatics</i> , 2018, 87, 372-374.	8.8	7
143	Thirst distress in outpatients with heart failure in a Mediterranean zone of Spain. <i>ESC Heart Failure</i> , 2021, 8, 2492-2501.	3.1	7
144	Telomere attrition in heart failure: a flow-FISH longitudinal analysis of circulating monocytes. <i>Journal of Translational Medicine</i> , 2018, 16, 35.	4.4	6

#	ARTICLE	IF	CITATIONS
145	Pulmonary vascular resistance versus pulmonary artery pressure for predicting right ventricular remodeling and functional tricuspid regurgitation. <i>Echocardiography</i> , 2018, 35, 1736-1745.	0.9	6
146	No need for urgent revisiting of kalaemia levels in guidelines despite use of mineralocorticoid receptor antagonists: bring in more evidence. <i>European Journal of Heart Failure</i> , 2018, 20, 1252-1254.	7.1	5
147	Cardiorenal interaction and heart failure outcomes. A role for insulin-like growth factor binding protein 2?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 835-843.	0.6	5
148	Impact of prescription patterns of antithrombotic treatment on atrial fibrillation-related ischemic stroke. <i>Current Medical Research and Opinion</i> , 2021, 37, 357-365.	1.9	5
149	Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes. <i>Journal of Clinical Medicine</i> , 2022, 11, 3558.	2.4	5
150	Statins in heart failure: not yet the end of the story?. <i>European Journal of Heart Failure</i> , 2013, 15, 708-709.	7.1	4
151	Validaci3n de la Barcelona Bio-Heart Failure Risk Calculator en una cohorte de Boston. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 80-81.	1.2	4
152	Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction?. <i>European Journal of Heart Failure</i> , 2016, 18, 576-576.	7.1	4
153	The Barcelona Bio-HF Calculator. <i>JACC: Heart Failure</i> , 2018, 6, 808-810.	4.1	4
154	Raz3n internacional normalizada y mortalidad de los pacientes con insuficiencia cardiaca y fibrilaci3n auricular tratados con antagonistas de la vitamina K. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 616-624.	1.2	4
155	International Normalized Ratio and Mortality Risk in Acute Heart Failure and Nonvalvular Atrial Fibrillation Patients Receiving Vitamin K Antagonists. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 616-624.	0.6	4
156	Mejorar la atenci3n m3dica mediante un4modelo integrado de4asistencia para4pacientes con4cardiopat4a isqu4mica o4fibrilaci3n auricular. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 779-780.	1.2	4
157	Impact4 of an integral assistance model between primary care and cardiology on the management of patients with ischemic heart disease or atrial fibrillation. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 103-111.	1.4	4
158	Seguimiento a largo plazo de pacientes sintom4ticos adultos con miocardiopat4a no compactada. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 169-171.	1.2	4
159	Myocardial interstitial fibrosis in the era of precision medicine. Biomarker-based phenotyping for a personalized treatment. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 248-254.	0.6	4
160	Prognostic value of lung ultrasound in chronic stable ambulatory heart failure patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 862-869.	0.6	4
161	Sacubitril/Valsartan as Antifibrotic Drug. <i>Journal of the American College of Cardiology</i> , 2020, 76, 515-517.	2.8	4
162	Heart failure is ejection fraction in motion. <i>European Journal of Heart Failure</i> , 2021, 23, 564-566.	7.1	4

#	ARTICLE	IF	CITATIONS
163	Cause of Death in Heart Failure Based on Etiology: Long-Term Cohort Study of All-Cause and Cardiovascular Mortality. <i>Journal of Clinical Medicine</i> , 2022, 11, 784.	2.4	4
164	Nutritional Status According to the GLIM Criteria in Patients with Chronic Heart Failure: Association with Prognosis. <i>Nutrients</i> , 2022, 14, 2244.	4.1	4
165	A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy. <i>Cancers</i> , 2022, 14, 2941.	3.7	4
166	Does Heart Failure Therapy Differ According to Patient Sex?. <i>Clinical Cardiology</i> , 2007, 30, 301-305.	1.8	3
167	Desnutrici3n y pron3stico en insuficiencia cardiaca. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 196-197.	1.2	3
168	Validation of the Barcelona Bio-Heart Failure Risk Calculator in a Cohort From Boston. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 80-81.	0.6	3
169	Brilliant violet fluorochromes in simultaneous multicolor flow cytometryâ€“fluorescence in situ hybridization measurement of monocyte subsets and telomere length in heart failure. <i>Laboratory Investigation</i> , 2016, 96, 1223-1230.	3.7	3
170	Biotherapies and biomarkers for cardiovascular diseases. <i>European Heart Journal</i> , 2017, 38, 1784-1786.	2.2	3
171	Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, , .	0.6	3
172	Lung ultrasound and biomarkers in primary care: Partners for a better management of patients with heart failure?. <i>Journal of Circulating Biomarkers</i> , 2020, 9, 8-12.	1.3	3
173	Myostatin serum levels in heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 1379-1379.	7.1	2
174	Concentraciones plasm3ticas de neprilisina: un nuevo marcador pron3stico en la insuficiencia cardiaca. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 535-536.	1.2	2
175	Potential role for clinical calibration to increase engagement with and application of home telemonitoring: a report from the HeartCycle programme. <i>ESC Heart Failure</i> , 2017, 4, 66-70.	3.1	2
176	Impact of a â€ˆstent for lifeâ€™™ initiative on post-ST elevation myocardial infarction heart failure: a 15Âyear heart failure clinic experience. <i>ESC Heart Failure</i> , 2018, 5, 101-105.	3.1	2
177	Una intervenci3n precoz para reducir reingresos a los 30 d3as en pacientes ancianos fr3giles con insuficiencia cardiaca mantiene su beneficio al a3o. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 261-263.	1.2	2
178	Mortality and Heart Failure Hospitalizations. The Need for an Exhaustive, Official, and Standardized Registry. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 988-990.	0.6	2
179	Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure. <i>ESC Heart Failure</i> , 2020, 7, 3320-3328.	3.1	2
180	The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations. <i>Scientific Reports</i> , 2021, 11, 5940.	3.3	2

#	ARTICLE	IF	CITATIONS
181	Mortalidad y reingresos por insuficiencia cardiaca: la necesidad de un registro oficial completo, abierto y homologable. Revista Espanola De Cardiologia, 2019, 72, 988-990.	1.2	2
182	Evoluci3n de las causas de muerte de pacientes con insuficiencia cardiaca cr3nica y funci3n sist3lica reducida. Revista Espanola De Cardiologia, 2020, 73, 783-784.	1.2	2
183	Clinical Determinants and Prognosis of Left Ventricular Reverse Remodelling in Non-Ischemic Dilated Cardiomyopathy. Journal of Cardiovascular Development and Disease, 2022, 9, 20.	1.6	2
184	Urinary NGAL in acute heart failure revisited: the game is not over yet. International Journal of Cardiology, 2022, 357, 113-114.	1.7	2
185	Respuesta. Revista Espanola De Cardiologia, 2008, 61, 654.	1.2	1
186	Nepriylsin Plasma Concentrations: A New Prognostic Marker in Heart Failure. Revista Espanola De Cardiologia (English Ed), 2016, 69, 535-536.	0.6	1
187	No urgent need for revisiting kalaemia guidelines: rebuttal. European Journal of Heart Failure, 2018, 20, 1256-1256.	7.1	1
188	Limitaci3n al flujo a3reo en pacientes con insuficiencia card3aca: prevalencia y factores asociados. Medicina Cl3nica, 2019, 153, 191-195.	0.6	1
189	An Early Post-discharge Intervention Planned to Reduce 30-day Readmissions in old and Frail Heart Failure Patients Remains Beneficial at 1 Year. Revista Espanola De Cardiologia (English Ed), 2019, 72, 261-263.	0.6	1
190	Preload dependence of pulmonary haemodynamics and right ventricular performance. Clinical Research in Cardiology, 2021, 110, 591-600.	3.3	1
191	Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?. PLoS ONE, 2021, 16, e0249674.	2.5	1
192	A new option for monitoring heart failure. First experience in Spain with CardioMEMS. Medicina Cl3nica, 2021, 156, 26-28.	0.6	1
193	1H-magnetic resonance spectroscopy lipoprotein profile in patients with chronic heart failure versus matched controls. Revista Espanola De Cardiologia (English Ed), 2021, , .	0.6	1
194	Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, 28-36.	1.5	1
195	Respuesta. Revista Espanola De Cardiologia, 2008, 61, 217-218.	1.2	0
196	Telemonitorizaci3n no invasiva en pacientes con insuficiencia cardiaca y servicios de urgencias hospitalarios. Respuesta. Revista Espanola De Cardiologia, 2011, 64, 949.	1.2	0
197	Analysis of Telephone Calls to a Heart Failure Unit: Reasons for the Call and Resource Use. Revista Espanola De Cardiologia (English Ed), 2013, 66, 914-915.	0.6	0
198	Comentarios al an3lisis de la demanda telef3nica en una unidad de insuficiencia cardiaca: motivos de consulta y utilizaci3n de recursos. Respuesta. Revista Espanola De Cardiologia, 2014, 67, 158-159.	1.2	0

#	ARTICLE	IF	CITATIONS
199	Comments on the Analysis of Telephone Calls to a Heart Failure Unit: Reasons for the Call and Resource Use. Response. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 158-159.	0.6	0
200	Morbidity and mortality in systolic heart failure also associated with raised serum neprilysin levels. Reply. <i>International Journal of Cardiology</i> , 2015, 190, 201.	1.7	0
201	Answer. Reverse remodeling in systolic heart failure. The ST2-R2 score: a puzzle yet to be solved?. <i>International Journal of Cardiology</i> , 2015, 187, 556.	1.7	0
202	Biomarkers in Heart Failure: ST2. , 2016, , 251-268.		0
203	Reply. <i>European Journal of Heart Failure</i> , 2017, 19, 1736-1736.	7.1	0
204	Letter by Fung etÂal Regarding Article, "Frailty and Clinical Outcomes in Heart Failure: A Systematic Review and Meta-analysis". <i>Journal of the American Medical Directors Association</i> , 2018, 19, 1143-1146.	2.5	0
205	Improving Medical Attention Through an Integral Care Model for Patients With Ischemic Heart Disease or Atrial Fibrillation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 779-781.	0.6	0
206	How a large registry can explain pathophysiology: The case of anemia in the heart failure syndromes. <i>International Journal of Cardiology</i> , 2020, 298, 72-73.	1.7	0
207	Tendencies in cause of death in patients with chronic heart failure and depressed systolic function. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 783-784.	0.6	0
208	Highly sensitive troponin T dynamics and prognosis in asymptomatic severe aortic stenosis. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 1065-1066.	0.6	0
209	Response. The ST2-SCD score in ambulatory heart failure patients. <i>International Journal of Cardiology</i> , 2020, 300, 207.	1.7	0
210	Left Ventricular Ejection Fraction in Heart Failure. <i>European Cardiology Review</i> , 2018, 13, 91.	2.2	0
211	Repeat physical stress echocardiography in asymptomatic severe aortic stenosis. <i>Cardiology Journal</i> , 2020, 27, 307-308.	1.2	0
212	DinÃmica de troponina T de alta sensibilidad y pronÃstico en pacientes con estenosis aÃrtica grave asintomÃtica. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 1065-1066.	1.2	0